A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Latest Information Update: 15 Apr 2024
At a glance
- Drugs Domvanalimab (Primary) ; Etrumadenant (Primary) ; Zimberelimab (Primary)
- Indications Brain metastases; Meningeal carcinomatosis; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2024 Planned End Date changed from 28 Feb 2029 to 30 Apr 2029.
- 09 Feb 2024 Planned primary completion date changed from 30 Nov 2024 to 31 Jan 2025.